Previously, we preliminarily observed the efficacy of LMQXM in treating ADHD and its ability to promote DA synthesis through clinical small-sample studies and animal experiments, and in the present study, we delved deeper into the potential mechanisms by which LMQXM modulates the DRD1/cAMP/PKA-CREB signaling pathway to bolster the synthesis of catecholamine neurotransmitters. The gene discussed is DRD1; the disease is attention deficit-hyperactivity disorder.